Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Evaluation of Bovine Mucosal Heparins Using Plasma-Based and Whole Blood Clotting Assays Troy LaBore, Brent Cudal, Monica Pastorious, Debra Hoppensteadt, Jawed Fareed, Walter Jeske, Jeanine Walenga. Loyola University Chicago Department of Pathology and Laboratory Medicine, Chicago, IL, USA |
Abstract
Background: Supply constraints and historical shortages of traditional heparin extraction sources have prompted investigation into alternatives for this widely used and essential anticoagulant. Bovine Mucosal Heparins (BMHs) offer a viable substitute for porcine heparin. There is significant evidence to suggest that BMHs exhibit similar activity to that of porcine heparin at USP potency standardized concentrations, laying the foundation for further inquiry into the application of these BMHs for medical prescriptions. The purpose of this study was to investigate the lot-to-lot variability of BMH-induced anticoagulation using in vitro plasma-based and whole blood assays. Materials and Methods: Twenty preclinical samples of BMH were obtained from KinMaster Chemicals (Passo Fundo, Brazil) and prepared in appropriate USP grade solute-solvent concentrations via serial dilution. BMH samples were supplemented with pooled citrated blood plasma or freshly collected whole blood. Clotting times (activated partial thromboplastin time; APTT, and thrombin time; TT) of BMH-supplemented plasma samples were measured using ACL 300 CTS and ST4, while coagulation time (activated clotting time; ACT, and thromboelastography; TEG) of supplemented whole blood was measured using Hemochrom 801 and TEG 5000. APTT clotting times were used to determine anticoagulant potency relative to the USP heparin standard. Results: APTT and TT assays demonstrated near-exponential prolongation of plasma clotting time as drug concentrations increased from 0.6-10 μg/ml. Similarly, ACT whole blood assays indicated consistent increases in total blood coagulation time in the presence of 2.5 μg/ml drug concentrations (182 ± 10 secs for BMHs) compared to a saline solution control (151 ± 5 secs). TEG whole blood coagulation experiments revealed increases in time of initiation of clot formation (R ~14 min BMH vs. ~10 min control) and maximal clot strength (K ~6 min BMH vs. ~2.5 min control) while displaying decreases in speed of fibrin accumulation (θ ~36° BMH vs. ~54° control) and strength of final clot formation (MA ~52 mm BMH vs. ~60 mm control). BMH potency values ranged from ~100-120 U/mg. Conclusion: Data across the variable experimental methods utilized in this study reveal a consistent prolongation of clotting and coagulation time in reference to the control solutions for each drug sample, supporting the efficacy of BMH-derived drugs and demonstrating acceptable lot-to-lot consistency. Further laboratory and clinical investigation is necessary to support these determinations before widespread implementation and adoption of this alternative source of heparin.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.